Literature DB >> 10959088

Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations.

H G Ahuja1, C A Felix, P D Aplan.   

Abstract

Chromosomal aberrations are frequently associated with therapy-related myelodysplastic syndromes and acute myelogenous leukemia (t-MDS/AML) and are thought to result from exposure to genotoxic drugs, including alkylating agents and DNA topoisomerase II poisons. The NUP98 gene on chromosome band 11p15 is involved in several different chromosomal aberrations that have been associated with t-MDS/AML. We have cloned the translocation breakpoints from two cases of t-MDS harboring a t(11;20)(p15;q11). Sequence analysis of the breakpoints from both cases revealed almost perfectly balanced translocations between NUP98 and TOP1. There were no known recombinogenic sequences identified at or near the breakpoints. However, four bp microduplications present at the translocation crossover points suggested that these translocations may have been initiated by 4 bp staggered double-stranded DNA breaks, which are known to be associated with the action of topoisomerase II. Given the history of patient exposure to topoisomerase II poisons, and the fact that these drugs stabilize staggered breaks with a 4 bp overhang, it seems possible that drug-induced topoisomerase II cleavage and subunit exchange was involved in these translocations. These results suggest that NUP98 is a recurrent target for therapy-related malignancies induced by multiagent chemotherapy, and suggest a role for DNA topoisomerase II poisons in the generation of these translocations. Published 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10959088     DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1013>3.0.co;2-t

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  Gene rearrangements induced by the DNA double-strand cleaving agent neocarzinostatin: conservative non-homologous reciprocal exchanges in an otherwise stable genome.

Authors:  Peng Wang; Jae Wan Lee; Yin Yu; Kristi Turner; Ying Zou; Colleen K Jackson-Cook; Lawrence F Povirk
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

Review 2.  Chromosomal translocations involving the MLL gene: molecular mechanisms.

Authors:  Peter D Aplan
Journal:  DNA Repair (Amst)       Date:  2006-06-21

Review 3.  Causes of oncogenic chromosomal translocation.

Authors:  Peter D Aplan
Journal:  Trends Genet       Date:  2005-10-28       Impact factor: 11.639

4.  Fusion of the NUP98 gene with the LEDGF/p52 gene defines a recurrent acute myeloid leukemia translocation.

Authors:  D J Hussey; S Moore; M Nicola; A Dobrovic
Journal:  BMC Genet       Date:  2001-11-23       Impact factor: 2.797

Review 5.  Molecular biology of therapy-related leukaemias.

Authors:  Melanie Joannides; David Grimwade
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

6.  Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif.

Authors:  E R Yassin; A M Abdul-Nabi; A Takeda; N R Yaseen
Journal:  Leukemia       Date:  2010-03-25       Impact factor: 11.528

7.  NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.

Authors:  Christopher Slape; Ying Wei Lin; Helge Hartung; Zhenhua Zhang; Linda Wolff; Peter D Aplan
Journal:  J Natl Cancer Inst Monogr       Date:  2008

8.  Molecular pathogenesis of secondary acute promyelocytic leukemia.

Authors:  M Joannides; A N Mays; A R Mistry; S K Hasan; A Reiter; J L Wiemels; C A Felix; F Lo Coco; N Osheroff; E Solomon; D Grimwade
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-10-24       Impact factor: 2.576

9.  TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo.

Authors:  Fernando Gómez-Herreros; Rocío Romero-Granados; Zhihong Zeng; Alejandro Alvarez-Quilón; Cristina Quintero; Limei Ju; Lieve Umans; Liesbeth Vermeire; Danny Huylebroeck; Keith W Caldecott; Felipe Cortés-Ledesma
Journal:  PLoS Genet       Date:  2013-03-07       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.